Torrent Pharmaceuticals is expanding its losartan recall due to the detection of the impurity NMBA. A full list of products affected by this recall can be found here:

We’re committed to ensuring adequate and safe supply of ARB medicines in an effort to mitigate shortages and improve access for patients. For a list of nitrosamine-free ARBs, see this link:

FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan

Valsartan recall update CDER Statement